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The role of EGCG, a major green tea catechin in breast cancer therapy is poorly understood. The present study tests
the hypothesis that EGCG can inhibit the activation of HIF-1α and NFκB, and VEGF expression, thereby suppressing
tumor angiogenesis and breast cancer progression. Sixteen eight-wk-old female mice (C57BL/6 J) were inoculated
with 10^6 E0771 (mouse breast cancer) cells in the left fourth mammary gland fat pad. Eight mice received EGCG
at 50–100 mg/kg/d in drinking water for 4 weeks. 8 control mice received drinking water only. Tumor size was
monitored using dial calipers. At the end of the experiment, blood samples, tumors, heart and limb muscles were
collected for measuring VEGF expression using ELISA and capillary density (CD) using CD31 immunohistochemistry.
EGCG treatment significantly reduced tumor weight over the control (0.37 ± 0.15 vs. 1.16 ± 0.30 g; P < 0.01), tumor
CD (109 ± 20 vs. 156 ± 12 capillary #/mm^2; P < 0.01), tumor VEGF expression (45.72 ± 1.4 vs. 59.03 ± 3.8 pg/mg;
P < 0.01), respectively. But, it has no effects on the body weight, heart weight, angiogenesis and VEGF expression in
the heart and skeletal muscle of mice. EGCG at 50 μg/ml significantly inhibited the activation of HIF-1α and NFκB as
well as VEGF expression in cultured E0771 cells, compared to the control, respectively. These findings support the
hypothesis that EGCG, a major green tea catechin, directly targets both tumor cells and tumor vasculature, thereby
inhibiting tumor growth, proliferation, migration, and angiogenesis of breast cancer, which is mediated by the
inhibition of HIF-1α and NFκB activation as well as VEGF expression.Introduction
The term ‘green tea’ refers to the product manufactured
from fresh tea leaves by steaming or drying at elevated
temperatures with the precaution to avoid oxidation of the
polyphenolic components known as catechins [1]. The
natural product (−)-epigallocatechin-3-gallate (EGCG) ac-
counts for 50-80% of catechins in green tea, representing
200–300 mg in a brewed cup of green tea [2]. Several
other catechins such as (−)-epicatechin-3-gallate (ECG),
(−)-epigallocatechin (EGC), and (−)-epicatechin (EC) are
found in lower abundance in green tea [3]. EGCG is de-
fined as a major green tea catechin that contributes to
beneficial therapeutic effects, including anti-oxidant, anti-* Correspondence: jgu@umc.edu
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reproduction in any medium, provided the orinflammatory, anti-cancer, and immunomodulatory effects
[4-6]. Studies conducted on cell-culture systems and ani-
mal models as well as human epidemiological studies
show that EGCG in green tea could afford protection
against a variety of cancer types [7]. Many studies have
shown that EGCG produces anti-cancer effect by modu-
lating the activity of mitogen-activated protein kinases
(MAPKs), IGF/IGF-1 receptor, Akt, NFκB and HIF-1α
[8-12]. A case–control study including 501 breast cancer
cases and 594 controls shows that green tea consumption
has a significant trend of decreasing risk in a dose-
dependent manner, after adjusting for potential con-
founding factors [13]. However, the investigations of green
tea or EGCG in breast cancer using animal model are very
limited, and the role of EGCG in breast cancer therapy is
poorly understood.This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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pendent on angiogenesis, the formation of new capillaries
from pre-existing blood vessels. Avascular tumors are
those that do not grow beyond a maximum size of 1 to
2 mm3 in the absence of neovascularization, and it may be
eliminated by a normal immune system [14]. Angiogenesis
requires stimulation of vascular endothelial cells through
the release of angiogenic factors. Of these, the vascular
endothelial growth factor (VEGF) is the most critical regu-
lator in the development of the vascular system and is
commonly overexpressed in a variety of human solid tu-
mors including breast cancer [15]. Cancer cells are under
greater hypoxia and oxidative stress than normal cells.
Oxygen radicals and hypoxia co-operatively promote
tumor angiogenesis [16]. Hypoxia causes the activation of
HIF-1, in which it stimulates VEGF expression. HIF-1
levels are also increased by oxygen radicals. In addition,
oxygen radicals activate NFκB that also increases VEGF
expression. VEGF is a key angiogenic factor that stimu-
lates the growth of tumors including breast cancer, in
which VEGF exerts paracrine (especially angiogenesis) and
autocrine (proliferation and migration) effects to promote
progression of breast cancer [17]. As mentioned above, we
believe that EGCG can block highly activated NFκB and
HIF-1α pathways in breast tumor. Therefore, we hypothe-
sizes that EGCG directly targets both of tumor cells and
tumor vasculature, thereby inhibiting tumor growth, pro-
liferation, migration, and angiogenesis of breast cancer,
which is mediated by the inhibition of HIF-1α and NFκB
activation as well as VEGF expression. Also, EGCG treat-
ment has no significant effects on the body weight, heart
weight, angiogenesis and VEGF expression in normal tis-
sues such as the heart and skeletal muscle.
To test this hypothesis, the present study aimed to de-
termine the following: (a) whether a relative high oral dose
of EGCG inhibits tumor growth, tumor angiogenesis, and
VEGF expression in an immunocompetent mouse model
(C57BL/6) of breast cancer; (b) whether oral EGCG treat-
ment affects angiogenesis and VEGF expression in normal
tissues such as the heart and skeletal muscle in the same
mice; and (c) whether EGCG inhibits proliferation, migra-
tion, VEGF expression, the activation of HIF-1α and NFκB
in cultured mouse and human breast cancer cells (E0771,
MCF-7 and MDA-MB-231).
Materials and methods
Chemicals and cell lines
EGCG was purchased from Sigma Chemical Co. (St. Louis,
MO). The mouse breast cancer cells (E0771) which were
originally isolated from an immunocompetent C57BL/6
mouse, were provided by Dr. Sirotnak FM at Memorial
Sloan Kettering Cancer Center, New York, NY [18]. Human
estrogen-receptor positive breast cancer (MCF-7) cells and
human triple negative breast cancer (MDA-MB-231) cellswere purchased from the American Type Culture Collec-
tion (Rockville, MD). All breast cancer cells were
maintained as monolayer cultures in RPMI Medium
1640 (GIBCO) supplemented with 10% FBS (HyClone),
100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25
μg/ml amphotericin B, and incubated at 37°C in a hu-
midified 5%CO2/air injected atmosphere.
Animal protocols
The protocols were carried out according to the guidelines
for the care and use of laboratory animals implemented by
the National Institutes of Health and the Guidelines of the
Animal Welfare Act and were approved by the University
of Mississippi Medical Center’s Institutional Animal Care
and Use Committee. 16 female C57BL/6 mice at 7 weeks
of age were purchased from Jackson Laboratory (Bar
Harbor, Maine). The mice were allowed to acclimate for
1 week with standard chaw diet (Teklad, Harlan Sprague
Dawley; Indianapolis, IN) and tap water before beginning
the experiments. The eight week old female mice (n = 16)
were inoculated with 10^6 E0771 cells suspended in 100 μl
of phosphate-buffered saline into the left fourth mammary
gland fat pad. Then, 8 mice received EGCG (25 mg/50 ml)
in drinking water for 4 weeks and 8 control mice received
drinking water only. Each mouse (20 g) usually drank 2 to
4 ml of water per day. Therefore, EGCG was given around
50 to 100 mg/kg/day to the mice. The body weight of the
mice was monitored weekly. Tumor size was monitored
every other day in two perpendicular dimensions paral-
lel with the surface of the mice using dial calipers. At
the end of the experiment, blood samples, tumors, heart
and limb muscles were collected for measuring VEGF
expression using ELISA and average microvascular
density (AMVD) or capillary density (CD) using CD31
immunohistochemistry.
Morphometric analysis of angiogenesis in tumor, the
heart and limb muscles
The quantification of blood vessels in mouse breast tumor,
the heart and limb muscle was determined with the modi-
fication of a previously reported method [17,19]. Briefly,
the tissues were fixed in 4% neutrally buffered paraformal-
dehyde. For the heart left ventricular and limb muscle
samples, consecutive thin transverse cryosections (5 μm)
were cut along the base-apex axis. Consecutive thin
cryosections (5 μm) of OCT compound (Sakura Finetek,
Torrance, CA) embedded tissue samples were fixed in
acetone at 4°C for 10 min. After washing in phosphate-
buffered saline (PBS), the sections were treated with 3%
H2O2 for 10 minutes to block endogenous peroxidase ac-
tivity and were blocked with normal rabbit serum. Then,
the sections were washed in PBS and incubated with rat
anti-mouse CD31 (PECAM-1) monoclonal antibody (BD
Pharmingen, San Diego, CA) at a 1:200 dilution overnight
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serum IgG at the same dilution. All sections were washed
in PBS containing 0.05% Tween-20, and were then incu-
bated with a 2nd antibody, mouse anti-rat IgG (Vector la-
boratories, Burlingame, CA) at a 1:200 dilution for 1 hour
at room temperature again followed by washing with PBS
containing 0.05% Tween-20. The sections were incubated
in a 1:400 dilution of Extravadin Peroxidase (Sigma, St.
Louis, MO) for 30 min. After washing in PBS containing
0.05% Tween-20, the sections were incubated in peroxid-
ase substrate (Vector laboratories, Burlingame, CA) for
5 min. The sections were washed in PBS containing 0.05%
Tween-20 and were counterstained with hematoxylin. A
positive reaction was indicated by a brown staining. The
microvascular vessels were quantified by manual counting
under light microscopy. A microscopic field (0.7884 mm2)
was defined by a grid laced in the eye-piece. At least 20
microscopic fields were randomly acquired from each
tumor for analysis. Any endothelial cell or cell cluster
showing antibody staining and clearly separated from an
adjacent cluster was considered to be a single, countable
microvessel. The value of average microvascular density
(AMVD) or capillary density (CD) was determined by cal-
culating the mean of the vascular counts per mm2
obtained in the microscopic fields for each tissue sample.
Measurements of protein levels of VEGF by ELISA
Protein levels of VEGF in plasma, breast tumor, the heart,
the limb muscle, and the medium cultured with E0771 cells
were determined using mouse VEGF ELISA kits (R&D Sys-
tems, Minneapolis, MN), according to the manufacturer’s
instructions. The total proteins of breast tumor, the heart,
the limb muscle, and cultured E0771 cells were extracted
using NE-PER Cytoplasmic Extraction Reagents (Pierce,
Rockford, IL), according to the manufacturer’s protocol.
The total protein concentration of these tissue extractions
was determined using a Bio-Rad Protein Assay (Bio-Rad
Laboratories, Hercules, CA). The protein concentrations of
VEGF were normalized and expressed as pictograms per
milligram of total tissue or cell extraction protein.
Proliferation assay of cultured breast cancer cells
The E0771, MCF-7, and MDA-MB-231cells were seeded
into 6-well tissue culture plates using RPMI Medium
1640 (GIBCO) supplemented with 10% FBS (HyClone),
100 U/ml penicillin, 100 μg/ml streptomycin, and 0.25 μg/
ml amphotericin B, and incubated at 37°C in a humidified
5%CO2/air injected atmosphere. When the monolayer
reached about 80% confluence, the cells were washed with
PBS and incubated with fresh RPMI Medium 1640 with
10% FBS in the absence and presence of EGCG (0, 10,
50 μg/ml) for 18 hours. 3H-thymidine incorporation assay
was used to determine the cell proliferation during the last
6 hours of incubation as previously described [20].Migration assay
Migration was determined using BD BioCoat Matrigel
Invasion Chamber (BD Bioscience Discovery Labware,
Sedford, MA) according to a previous study, in which only
invasive cells digested the matrix and moved through the
insert membrane [21]. 1 × 105 E0771 cells per well in
0.5 ml medium (RPMI Medium 1640) were seeded in the
matrigel-coated upper compartment (insert) of a Transwell
(24-well format, 8-μm pore) in the absence of and presence
of EGCG (0, 10, 20, 50 μg/ml) and the medium with 10%
FBS was added to the lower part of the well. After over-
night incubation at 37°C and 5% CO2, cells on the upper
surface of the insert were removed using a cotton wool
swab. Migrated cells on the lower surface of the insert
were stained using DiffQuit (Dada Behring, Düdinen,
Switzerland). The images of migrated cells were taken
and the number of migrated cells was counted using a
microscope (Leica, Germany) in a 20× objective.
HIF-1α and NFκB activation (motif binding) assays
We determined HIF-1α and NFκB activation in cultured
E0771 cells in the absence and presence of EGCG (0 and
50 mg/ml) to investigate whether the down-regulation of
VEGF by EGCG is associated with the inhibition of HIF-1α
and NFκB activation (n = 6). The nuclear proteins were
extracted by using Active Motif (Carlsbad, CA) nuclear ex-
tract kit. 20 μg nuclear proteins from each sample was used
in the TransAM HIF-1α or NFκB p65 kit (Active Motif),
which can measure the binding of activated HIF-1α or
NFκB to its consensus sequence attached to a microwell
plate, according the manufacturer’s instructions.
Statistical analysis
All determinations were performed in duplicated sets.
Where indicated, data is presented as mean ± SE. Statisti-
cally significant differences in mean values between the
two groups were tested by an unpaired Student’s t-test.
Linear regression was performed by the correlation ana-
lysis between two continuous variables. A value of P < 0.05
was considered statistically significant. All statistical calcu-
lations were performed using SPSS software (SPSS Inc.,
Chicago, IL).
Results
A relative high oral dose of EGCG significantly inhibits the
progression of breast cancer growth
We used a mouse breast cancer model that mimics the hu-
man disease, in which the mouse breast adenocinoma
(E0771) cells were injected into the pad of the fourth mam-
mary gland of female immunocompetent mice (C57BL/6).
Immediately after the inoculation of E0771 cells, the eight
week old female mice (n = 8) were given EGCG at 50 to
100 mg/kg/day in drinking water for four weeks and the
control group (n = 8) was given regular drinking water only.
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pendicular dimensions parallel with the surface of the mice
using dial calipers. As indicated in Figure 1A, the tumor
cross section area was significantly reduced in the EGCG-
treated group compared to the control group two weeks
after the breast cancer inoculation. At the end of experi-
ment, the tumor cross section area was reduced by 65%
(P < 0.01) in EGCG-treated group compared to the control
group (Figure 1A), which was consistent with the reduction
in tumor weight (Figure 1B) in EGCG-treated group com-
pared to the control group (0.37 ± 0.15 vs. 1.16 ± 0.30 g;
P <0.01). Clearly, EGCG treatment at 50 to 100 mg/kg/d in
drinking water significantly inhibited the progression of
breast cancer growth in the female mice by decreasing the
tumor size and reducing the growth curve of breast cancer.
However, there was no significant difference in the body
weight, heart weight, kidney weight, or urinary protein be-
tween the EGCG-treated mice and the control mice.
EGCG suppresses breast tumor angiogenesis and VEGF
expression in mice
Growth and expansion of tumor mass are strictly



































































Figure 1 The inhibition of the progression of breast cancer
growth by oral EGCG in the immunocompetant female mice
(C57BL/6) allografted with mouse breast cancer (E0771) cells.
EGCG at 50 to 100 mg/kg/day in drinking water for four weeks
significantly reduced a growth curve of breast cancer monitored by
the tumor cross section area by 65% (Figure 1A, P < 0.01; n = 8) and
tumor weight (Figure 1B, 0.37 ± 0.15 vs. 1.16 ± 0.30 g; P < 0.01; n = 8),
compared to the control group.permits rapid tumor growth by providing an exchange of
nutrients, oxygen, and paracrine stimuli to the tumor [22].
Therefore, in this study, we used a morphometric analysis
of immunohistochemical staining for CD31 to determine
the effect of EGCG on breast tumor angiogenesis in mice.
Representative images of CD31 staining of the breast can-
cer tumors showed that the EGCG-treated tumor had
lesser microvessels than the control tumor (Figure 2A).
Morphometric analysis (Figure 2A) indicated that PDTC
treatment caused a significant decrease in average micro-
vessel density (AMVD, the number of microvessels per
mm2 area) of breast tumors compared to the control
breast tumors (109 ± 20 vs. 156 ± 12 microvessels number
per mm^2; n = 8; P < 0.01). These results also suggest that
a pronounced decrease in tumor angiogenesis is associated
with a decrease in tumor size of breast cancer tumor in the
female mice treated with EGCG compared to those in the
control mice. Figure 2B also demonstrated that EGCG
treatment reduced plasma VEGF levels over the control
mice (26.48 ± 3.76 vs. 40.79 ± 3.5 pg/ml; n = 8; P < 0.01)
and tumor VEGF expression over the control mice
(45.72 ± 1.4 vs. 59.03 ± 3.8 pg/mg; n = 8; P < 0.01). These
findings suggest that the inhibition of tumor angiogen-
esis in mice by EGCG is due to the down-regulation of
VEGF because VEGF is a key angiogenic factor.EGCG directly inhibits proliferation and migration of
breast cancer cells
We used a 3H-thymidine incorporation assay to de-
termine the effects of EGCG on the proliferation of
cultured mouse breast cancer cells (E0771), human es-
trogen receptor positive breast cancer cells (MCF-7),
and triple negative breast cancer cells (MDA-MB-231).
Figure 3A showed that E0771 cells treated with EGCG
caused a dose-related decrease in 3H-thymidine incorp-
oration, decreasing by 22% at 10 μg/ml and by 77%
at 50 μg/ml, compared to the control group (n = 6;
P < 0.01). We examined the inhibitory effect of EGCG
on E0771 cell migration using BD BioCoat Matrigel In-
vasion Chamber. Figure 3B demonstrates that EGCG at
10, 20, and 50 μg/ml caused a dose-dependent reduc-
tion of migrated breast cancer (E0771) cells, decreasing
by 25%, 48%, and 71%, respectively, compared to the
control group (n = 6; P < 0.01). In the another experi-
ment, as shown in Figure 3C, we demonstrated that
EGCG at 50 μg/ml significantly inhibited the prolifera-
tion of human estrogen receptor positive breast cancer
cells (MCF-7) and triple negative breast cancer cells
(MDA-MB-231) by 91% and 52%, respectively, com-
pared to the control group (n = 6; P < 0.01), but not at
10 μg/ml. These in vitro findings illustrate that EGCG


















































































































Control 200X EGCG 200X
A
B
Figure 2 Oral EGCG at 50–100 mg/kg/d in drinking water significantly reduced intratumoral microvessel density (Panel A: 109 ± 20 vs.
156 ± 12 microvessel #/mm^2; P < 0.01), plasma VEGF levels (Panel B; 26.48 ± 3.76 vs. 40.79 ± 3.5 pg/ml; P < 0.01), and tumor VEGF
expression (Panel B; 45.72 ± 1.4 vs. 59.03 ± 3.8 pg/mg; P < 0.01) over the control, respectively in mice (n = 8). The digital images show
CD31 immunohistochemistry staining in OCT-embedded cryosections of mouse breast cancer tumors obtained from a control (Figure 2A) or
EGCG-treated (Figure 2A) mouse.
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associated with the inhibition of HIF-1α and NFκB
activation
HIF-1 and NFκB pathways are highly activated in breast
tumor, in which they can co-operatively promote tumor
angiogenesis by increasing VEGF expression [16]. We used































































Figure 3 EGCG caused a dose-related inhibition in 3H-thymidine incorp
(Panel A, n = 6, P < 0.01), and in migration (Panel B, n = 6, P < 0.01) in cu
EGCG at 50 μg/ml significantly inhibited the proliferation in cultured MCF-7
P < 0.01), respectively.Binding) assays to determine whether EGCG could sup-
press HIF-1α and NFκB activation and VEGF expression
in cultured mouse breast cancer (E0771) cells. Figure 4A
showed that EGCG at 50 μg/ml significantly inhibited
VEGF expression (1752 ± 49 vs. 2254 ± 91 pg/mg; n = 6;
P < 0.01) in cultured E0771 cells, compared to the
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ltured E0771 cells, compared to the control group. In Panel C,









































































Figure 4 EGCG at 50 μg/ml significantly inhibited VEGF expression (Panel A, 1752 ± 49 vs. 2254 ± 91 pg/mg, n = 6, P < 0.01), the
activation of HIF-1α (Panel B, 0.11 ± 0.02 vs. 0.24 ± 0.02, n = 6, P < 0.01) and NFκB (Panel C, 1.15 ± 0.21 vs. 1.61 ± 0.32; n = 6, P < 0.01) in
cultured E0771 cells, compared to the control, respectively.
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(0.11 ± 0.02 vs. 0.24 ± 0.02; P < 0.01; Figure 4B) and NFκB
(1.15 ± 0.21 vs. 1.61 ± 0.32; n = 6; P < 0.01; Figure 4C),
compared to the control, respectively. These results sug-
gest that the inhibition of HIF-1α and NFκB activation
contributes to the down-regulation of VEGF expression.
Oral EGCG treatment has no effects on angiogenesis and
VEGF expression in normal tissues such as the heart and
skeletal muscle in mice
The data showed that there was no significant difference
in the body weight (22.38.25 ± 0.51 vs. 22.94 ± 0.57; n = 8;
P = 0.9437), heart weight (84.7 ± 11.2 vs. 85.1 vs. 10.6 mg;
n = 8; P = 0.3546), or kidney weight (237.5 ± 9.2 vs. 240.1 ±
8.9 mg; n = 8; P = 0.3735) between the EGCG-treated
mice and the control mice. Figure 5A showed that EGCG
treatment did not affect the capillary density (number of
capillary/mm^2 area) (3270 ± 162 vs. 3103 ± 226 #/mm^2;
n = 8; P = 0.5215) analyzed by CD31 immunochemistry
and morphometric analysis, and VEGF expression (261 ± 22
vs. 245 ± 19 pg/mg; n = 8; P = 0.4517) determined by ELISA
in the mouse heart, compared to the control group, re-
spectively. Figure 5B showed that there was no significant
difference in the capillary density (370 ± 55 vs. 381 ± 44
#/mm^2; n = 8; P = 0.5401), and VEGF expression (225 ± 16
vs. 214 ± 20 pg/mg; n = 8; P = 0.7825) in the limb skel-
etal muscles between the EGCG-treated mice and the
control mice, respectively. These findings illustrate that
EGCG does not significantly affect angiogenesis and
VEGF expression in the normal tissues such as the heart
and skeletal muscles.
Discussion
The major new findings from this study include: 1) a
relative high oral dose of EGCG significantly inhibits the
progression of mouse breast cancer growth in female
immunocompetent mice; 2) EGCG significantly sup-
presses breast tumor angiogenesis and VEGF expression
in these mice; 3) EGCG treatment does not significantlyaffect angiogenesis and VEGF expression in the normal
tissues such as the heart and skeletal muscles in the
same experiment; 4) EGCG directly inhibits proliferation
and migration of cultured mouse and human breast can-
cer cells; and 5) the down-regulation of VEGF expression
by EGCG is associated with the inhibition of HIF-1α and
NFκB activation. These findings support the hypothesis
that EGCG, a major green tea catechin directly targets
both of tumor cells and tumor vasculature, thereby inhi-
biting tumor growth, proliferation, migration, and an-
giogenesis of breast cancer, which is mediated by the
inhibition of HIF-1α and NFκB activation as well as VEGF
expression. Also, EGCG treatment has no significant ef-
fects on angiogenesis and VEGF expression in normal tis-
sues such as the heart and skeletal muscle.
An important finding of this study is that a relative high
oral dose of EGCG treatment at 50 to 100 mg/kg/day in
drinking water significantly slows a growth curve of breast
cancer in C57BL/6 female mice compared to the control
group, which is characterized by 65% and 68% reduction in
the tumor cross section area and tumor weight, respect-
ively. Clearly, oral EGCG treatment is very effective in
suppressing progression of breast cancer in a wild type im-
munocompetent mouse model. Ullmann et al. reported
that peak plasma concentrations were greater than 3 μg/ml
after oral dose of 1600 mg in healthy human subjects [23].
We believe that oral dose of 50 to 100 mg/kg/day in
human can reach the effective plasma concentrations of
EGCG against breast cancer. Recent methods developed
for the stereoselective total synthesis of EGCG, and struc-
turally related catechins, could provide new sources of
these compounds for biomedical use [24]. Our next step is
clinical trial for EGCG in breast cancer therapy.
Cancer cells are under greater hypoxia and oxidative
stress than normal cells. 8-hydroxy-2’-deoxyguanosine, a
major marker of constitutive oxidative stress is almost
10 times more prevalent in invasive ductal breast carcin-
oma cells than in normal control samples from the same
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A
Figure 5 EGCG treatment did not affect the capillary density (3270 ± 162 vs. 3103 ± 226 #/mm^2; n = 8; P = 0.5215), and VEGF
expression (261 ± 22 vs. 245 ± 19 pg/mg; n = 8; P = 0.4517) in the mouse heart, compared to the control group (Panel A), respectively.
There was no significant difference in the capillary density (370 ± 55 vs. 381 ± 44 #/mm^2; n = 8; P = 0.5401), and VEGF expression (225 ± 16 vs.
214 ± 20 pg/mg; n = 8; P = 0.7825) in the limb skeletal muscles between the EGCG-treated mice and the control mice (Panel B), respectively. The
digital images show CD31 immunohistochemistry staining in OCT-embedded cryosections of the heart (Panel A) and the limb muscle (Panel B)
of control mouse and EGCG-treated mouse, respectively.
Gu et al. Vascular Cell 2013, 5:9 Page 7 of 10
http://www.vascularcell.com/content/5/1/9species (ROS) by alterations to metabolic pathways in
tumor cells [26], an inadequate tumor vascular network
[16], and macrophage infiltration of the tumor [27]. Breast
carcinomas support their growth by stimulating angiogen-
esis. Blood flow within these new vessels is often chaotic,
causing periods of hypoxia followed by reperfusion. The
generation of ROS by reperfusion further causes oxidative
stress within breast carcinomas. Also, a breast carcinoma
rapidly outgrows its blood supply, leading to glucose
deprivation and hypoxia. Glucose deprivation rapidly in-
duces oxidative stress within breast carcinoma cells [28].
Clearly, hypoxia and oxidative stress are found together
within the breast carcinoma, in which VEGF production
can be augmented by synergy between oxygen radicals
and tumor hypoxia. Oxygen radicals and hypoxia co-
operatively promote tumor angiogenesis [16]. Hypoxia
causes the activation of HIF-1, in which it stimulates
VEGF expression. HIF-1 levels are also increased by oxy-
gen radicals. In addition, oxygen radicals activate NFκB
that also increases VEGF expression. Thus, the compound
blocking HIF-1and NFκB pathways can significantly in-
hibit VEGF expression and angiogenesis in carcinomas in-
cluding breast carcinomas.In this study, we found that the significant inhibitions of
tumor growth and tumor angiogenesis of breast cancer in
female mice by EGCG were associated with suppressing
the activation of HIF-1α and NFκB, and decreasing VEGF
expression in breast carcinoma cells. VEGF is a key angio-
genic factor that stimulates the growth of tumors including
breast cancer, in which VEGF exerts paracrine (especially
angiogenesis) and autocrine (proliferation and migration)
effects to promote progression of breast cancer [17]. VEGF
overexpression and the activation of HIF-1α and NFκB
pathways in breast cancer are strongly linked to rapid
growth of tumors and worse prognosis [16,29,30]. Oxygen
radicals and hypoxia co-operatively promote tumor angio-
genesis, in which VEGF overexpression is stimulated by the
activation of HIF-1α and NFκB pathways in breast cancer
[16]. The present findings indicate that EGCG significantly
inhibits VEGF expression by suppressing the activation of
HIF-1α and NFκB pathways, thereby inhibiting tumor
growth, proliferation, migration, and angiogenesis of breast
cancer. Our results are supported by the previous findings
as follows: 1) EGCG suppressed tumor growth by blocking
the induction of VEGF in human colon carcinoma cells
[31]; 2) EGCG inhibited VEGF/VEGFR axis by suppressing
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[32]; and 3) EGCG inhibited cancer progression by decreas-
ing NFκB activation [33]. Progression stage is the final
phase of cancer development, an uncontrolled growth of
cancer cells occurs. In this stage cancer cells are under
greater hypoxia and oxidative stress, in which many tran-
scription factors, such as HIF-1α and NFκB, are activated
leading to transmit aberrant signals resulting in abnormal
functions such as tumor angiogenesis, cancer invasiveness
and metastasis. Present findings illustrate that EGCG can
inhibit multiple key cellular signals resulting in inhibiting
tumor angiogenesis and breast cancer progression. Also, ac-
cumulating evidence shows that EGCG can target all stages
of cancer development by blocking multiple cellular pro-
teins involved in diverse cellular signal transduction path-
ways: proliferation, differentiation, apoptosis, angiogenesis
or metastasis [34]. In future study, we will investigate the
therapeutic potentials of EGCG combined with VEGF re-
ceptor inhibitor, Notch inhibitor, HIF-1 inhibitor, or NFκB
blocker in breast cancer therapy.
In present study, we demonstrated that EGCG treat-
ment reduced plasma VEGF levels by 35% over the con-
trol mice, which was associated with more than 65%
reduction of tumor weight in EGCG treated breast can-
cer mice, compared to untreated breast cancer mice.
These findings are consistent with breast cancer pa-
tients that EGCG treatment reduced serum levels of
VEGF [35]. A study on 200 women showed that serum
VEGF levels were significantly higher in breast cancer
patients compared to control [36]. Systemic VEGF
levels were reduced significantly in the breast cancer pa-
tients following tumor excision [36]. We believe that
oral EGCG treatment could reduce the tumor-related
blood VEGF levels.
Interestingly, the present study shows that EGCG treat-
ment does not significantly affect angiogenesis and VEGF
expression in the normal tissues such as the heart and
skeletal muscles in the same experiment. The present
study first time shows that oral EGCG treatment signifi-
cantly inhibits angiogenesis, VEGF expression, and growth
in breast tumor, but no such effects on the normal tissues
such as the heart and limb muscles in the same mice. The
different effects of EGCG in tumor and normal tissues
can be explained by that cancer cells are under greater
hypoxia and oxidative stress than normal cells. VEGF ex-
pression and angiogenesis are very stable in normal ma-
tured tissues in which they are regulated by metabolic
balance within the tissue. However, angiogenesis is stimu-
lated by significantly increased VEGF levels, activated
HIF-1α and NFκB pathways in cancer. We also found that
there was no significant difference in the body weight,
heart weight, or kidney weight between EGCG-treated
mice and the control mice. This is an exciting possibility,
because EGCG is a drug of low toxicity.Antiangiogenic therapy is an attractive approach for can-
cer treatment including breast cancer, in which these agents
include monoclonal antibodies (mAbs) and the tyrosine
kinase inhibitors (TKIs) of VEGF pathway. Implicated in
many physiological processes, VEGF pathway inhibition
can lead to on-target side effects, such as hypertension, pro-
teinuria, thromboembolic events, or congestive heart failure
[37-39]. The incidence of hypertension rate was up to 35%
with bevacizumab, a monoclonal antibody against VEGF-A
[40,41]. Ultimately, considering the modest clinical benefit
on the one hand, and the increase in toxicity on the other,
the US Food and Drug Administration withdraw its ap-
proval of the breast cancer treatment for bevacizumab [42].
As mentioned above, EGCG is a drug of low toxicity, and
significantly inhibits angiogenesis in breast tumor (under
greater oxidative stress), but not in the normal tissues (no
oxidative stress) such as the heart and limb muscles in the
same mice. Thus, EGCG may overcome the existing bar-
riers - the mAbs and TKIs of VEGF pathway-induced on-
target side effects. However, the further studies are needed.
In conclusion, our results indicate that oral adminis-
tration of EGCG, a major green tea catechin, signifi-
cantly inhibits tumor growth and tumor angiogenesis of
breast cancer, but no effect on angiogenesis in the heart
and limb muscles in an immunocompetent mouse
model using mouse breast cancer (E0771) cells. EGCG
directly suppresses the proliferation or migration of
cultured mouse breast cancer cells as well as the pro-
liferation of human breast cancer cells (MCF-7 and
MDA-MB-231). These anticancer effects of EGCG seem
to be mediated by blocking multiple intracellular signal-
ing cascades such as HIF-1α and NFκB pathways. The
mechanistic advance of EGCG on inhibiting tumor
angiogenesis is very unique, in which EGCG does not
target angiogenesis in normal tissue. Accumulating evi-
dence indicates that EGCG displays a vast array of
cellular effects involved in all stages of cancer develop-
ment. The multiple targets on cancer and less side ef-
fects of EGCG will lead a successful targeted therapy for
cancers including breast cancer. The potential thera-
peutic targets of EGCG in cancer therapy are needed to
be further explored. Our next step is clinical trial for
EGCG in breast cancer therapy. The combination of
EGCG with other targeted compounds such as VEGF
receptor inhibitor, Notch inhibitor or HIF-1 inhibitor
could lead to a very effective specific targeted breast
cancer therapy.
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